Overview
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.
Eligibility
Inclusion Criteria:
- Aged 18 to 65 years;
- Providing written informed consent;
- Perform elective minimally invasive endoscopic surgery (laparoscopic surgery, thoracoscopic surgery) undergoing general anesthesia.
Exclusion Criteria:
- Known to be allergic to dexamethasone;
- Any systemic glucocorticoids within 3 months before trial entry;
- History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
- Cognitive impairment or severe mental illness;
- Uncontrolled diabetes or infectious diseases;
- Pregnancy or breastfeeding.